Macrocycle Therapeutics to Treat Life-threatening Diseases

[1] A Peptidomimetic Antibiotic Interacts with the Periplasmic Domain of LptD from Pseudomonas aeruginosa[J]. Andolina, Gloria;Bencze, Laszlo-Csaba;Zerbe, Katja;Mueller, Maik;Steinmann, Jessica;Kocherla, Harsha;Mondal, Milon;Sobek, Jens;Moehle, Kerstin;Malojcic, Goran;Wollscheid, Bernd;Robinson, John A. ACS CHEMICAL BIOLOGY, 2018(03)

[2] [Anonymous], 2012, Drug Discov Today Technol, V9, pe1, DOI 10.1016/j.ddtec.2011.07.006

[3] A HOT-SPOT OF BINDING-ENERGY IN A HORMONE-RECEPTOR INTERFACE[J]. CLACKSON, T;WELLS, JA. SCIENCE, 1995(5196)

[4] Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study[J]. Cortes, Javier;O'Shaughnessy, Joyce;Loesch, David;Blum, Joanne L.;Vahdat, Linda T.;Petrakova, Katarina;Chollet, Philippe;Manikas, Alexey;Dieras, Veronique;Delozier, Thierry;Vladimirov, Vladimir;Cardoso, Fatima;Koh, Han;Bougnoux, Philippe;Dutcus, Corina E.;Seegobin, Seth;Mir, Denis;Meneses, Nicole;Wanders, Jantien;Twelves, Chris. LANCET, 2011(9769)

[5] A mouse model for evaluation of efficacy and concomitant toxicity of anti-human CXCR4 therapeutics[J]. Costa, Maria Jose;Kudaravalli, Jyothirmayee;Liu, Wen-Hui;Stock, Jeffrey;Kong, Sophanna;Liu, Shu-Hui. PLOS ONE, 2018(03)

[6] Discovery of novel, highly potent and selective β-hairpin mimetic CXCR4 inhibitors with excellent anti-HIV activity and pharmacokinetic profiles[J]. DeMarco, Steven J.;Henze, Heiko;Lederer, Alexander;Moehle, Kerstin;Mukherjee, Reshmi;Romagnoli, Barbara;Robinson, John A.;Brianza, Federico;Gombert, Frank O.;Lociuro, Sergio;Ludin, Christian;Vrijbloed, Jan Willem;Zumbrunn, Juerg;Obrecht, Jean-Pierre;Obrecht, Daniel;Brondani, Vincent;Hamy, Francois;Klimkait, Thomas. BIOORGANIC & MEDICINAL CHEMISTRY, 2006(24)

[7] Phase III Prospective Randomized Double-Blind Placebo-Controlled Trial of Plerixafor Plus Granulocyte Colony-Stimulating Factor Compared With Placebo Plus Granulocyte Colony-Stimulating Factor for Autologous Stem-Cell Mobilization and Transplantation for Patients With Non-Hodgkin's Lymphoma[J]. DiPersio, John F.;Micallef, Ivana N.;Stiff, Patrick J.;Bolwell, Brian J.;Maziarz, Richard T.;Jacobsen, Eric;Nademanee, Auayporn;McCarty, John;Bridger, Gary;Calandra, Gary. JOURNAL OF CLINICAL ONCOLOGY, 2009(28)

[8] CXCR4 inhibition enhances radiosensitivity, while inducing cancer cell mobilization in a prostate cancer mouse model[J]. Domanska, Urszula M.;Boer, Jennifer C.;Timmer-Bosscha, Hetty;van Vugt, Marcel A. T. M.;Hoving, Hilde D.;Kliphuis, Nathalie M.;Rosati, Stefano;van der Poel, Henk G.;de Jong, Igle Jan;de Vries, Elisabeth G. E.;Walenkamp, Annemiek M. E. CLINICAL & EXPERIMENTAL METASTASIS, 2014(07)

[9] The exploration of macrocycles for drug discovery - an underexploited structural class[J]. Driggers, Edward M.;Hale, Stephen P.;Lee, Jinbo;Terrett, Nicholas K. NATURE REVIEWS DRUG DISCOVERY, 2008(07)

[10] Ermert P, 2015, RSC DRUG DISCOV, V40, P283

[1] A Peptidomimetic Antibiotic Interacts with the Periplasmic Domain of LptD from Pseudomonas aeruginosa[J]. Andolina, Gloria;Bencze, Laszlo-Csaba;Zerbe, Katja;Mueller, Maik;Steinmann, Jessica;Kocherla, Harsha;Mondal, Milon;Sobek, Jens;Moehle, Kerstin;Malojcic, Goran;Wollscheid, Bernd;Robinson, John A. ACS CHEMICAL BIOLOGY, 2018(03)

[2] [Anonymous], 2012, Drug Discov Today Technol, V9, pe1, DOI 10.1016/j.ddtec.2011.07.006

[3] A HOT-SPOT OF BINDING-ENERGY IN A HORMONE-RECEPTOR INTERFACE[J]. CLACKSON, T;WELLS, JA. SCIENCE, 1995(5196)

[4] Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study[J]. Cortes, Javier;O'Shaughnessy, Joyce;Loesch, David;Blum, Joanne L.;Vahdat, Linda T.;Petrakova, Katarina;Chollet, Philippe;Manikas, Alexey;Dieras, Veronique;Delozier, Thierry;Vladimirov, Vladimir;Cardoso, Fatima;Koh, Han;Bougnoux, Philippe;Dutcus, Corina E.;Seegobin, Seth;Mir, Denis;Meneses, Nicole;Wanders, Jantien;Twelves, Chris. LANCET, 2011(9769)

[5] A mouse model for evaluation of efficacy and concomitant toxicity of anti-human CXCR4 therapeutics[J]. Costa, Maria Jose;Kudaravalli, Jyothirmayee;Liu, Wen-Hui;Stock, Jeffrey;Kong, Sophanna;Liu, Shu-Hui. PLOS ONE, 2018(03)

[6] Discovery of novel, highly potent and selective β-hairpin mimetic CXCR4 inhibitors with excellent anti-HIV activity and pharmacokinetic profiles[J]. DeMarco, Steven J.;Henze, Heiko;Lederer, Alexander;Moehle, Kerstin;Mukherjee, Reshmi;Romagnoli, Barbara;Robinson, John A.;Brianza, Federico;Gombert, Frank O.;Lociuro, Sergio;Ludin, Christian;Vrijbloed, Jan Willem;Zumbrunn, Juerg;Obrecht, Jean-Pierre;Obrecht, Daniel;Brondani, Vincent;Hamy, Francois;Klimkait, Thomas. BIOORGANIC & MEDICINAL CHEMISTRY, 2006(24)

[7] Phase III Prospective Randomized Double-Blind Placebo-Controlled Trial of Plerixafor Plus Granulocyte Colony-Stimulating Factor Compared With Placebo Plus Granulocyte Colony-Stimulating Factor for Autologous Stem-Cell Mobilization and Transplantation for Patients With Non-Hodgkin's Lymphoma[J]. DiPersio, John F.;Micallef, Ivana N.;Stiff, Patrick J.;Bolwell, Brian J.;Maziarz, Richard T.;Jacobsen, Eric;Nademanee, Auayporn;McCarty, John;Bridger, Gary;Calandra, Gary. JOURNAL OF CLINICAL ONCOLOGY, 2009(28)

[8] CXCR4 inhibition enhances radiosensitivity, while inducing cancer cell mobilization in a prostate cancer mouse model[J]. Domanska, Urszula M.;Boer, Jennifer C.;Timmer-Bosscha, Hetty;van Vugt, Marcel A. T. M.;Hoving, Hilde D.;Kliphuis, Nathalie M.;Rosati, Stefano;van der Poel, Henk G.;de Jong, Igle Jan;de Vries, Elisabeth G. E.;Walenkamp, Annemiek M. E. CLINICAL & EXPERIMENTAL METASTASIS, 2014(07)

[9] The exploration of macrocycles for drug discovery - an underexploited structural class[J]. Driggers, Edward M.;Hale, Stephen P.;Lee, Jinbo;Terrett, Nicholas K. NATURE REVIEWS DRUG DISCOVERY, 2008(07)

[10] Ermert P, 2015, RSC DRUG DISCOV, V40, P283